Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | CASP6 | P55212 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28385733 | 0.98 | MAOA (0.43) | MAOACASP6MAPTALDH1A1HPGD | |
| SCHEMBL679952 | 0.79 | CYP19A1 (0.55) | CASP6MAPTALDH1A1HPGDALOX15 | |
| SCHEMBL31551042 | 0.79 | CYP19A1 (0.55) | CASP6MAPTALDH1A1HPGDALOX15 | |
| Hydrochloric Acid SCHEMBL15621988 | 0.77 | CYP19A1 (0.53) | CASP6MAPTALDH1A1HPGDALOX15 | |
| SCHEMBL27654823 | 0.77 | CYP19A1 (0.53) | CASP6MAPTALDH1A1HPGDALOX15 | |
| SCHEMBL23263176 | 0.72 | CASP6 (0.46) | MAOACASP6MAPTALDH1A1HPGD | |
| SCHEMBL27757834 | 0.72 | KDM4E (0.52) | MAOACASP6MAPTALDH1A1HPGD | |
| SCHEMBL6217782 | 0.72 | CA12 (0.57) | CASP6MAPTALDH1A1HPGDALOX15 | |
| SCHEMBL28408631 | 0.71 | KDM4E (0.50) | MAOACASP6MAPTALDH1A1HPGD | |
| SCHEMBL26259990 | 0.71 | BRD4 (0.45) | MAPTALDH1A1HPGDALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113365610-A | Methods of making and delivering bisantrene formulations | 现代化制药公司 | 2021-09-07 | — | — | CN | claimed |
| CN-118307674-A | Antibody molecules against CD73 and uses thereof | 诺华股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118119406-A | Combination radiation therapy | 泰利斯制药(创新)有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118021943-A | Combination therapy of chimeric antigen receptor and PD-1 inhibitor | 诺华股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117959417-A | Combination therapy of chimeric antigen receptor and PD-1 inhibitor | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-110785187-B | Antibody molecules against CD73 and uses thereof | 诺华股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-116769050-A | CD229 CAR T cells and methods of use thereof | 犹他大学研究基金会 | 2023-09-19 | — | — | CN | disclosed |
| CN-116615258-A | Compositions and methods for in vivo production of CAR-expressing cells | 诺华股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116478927-A | Human mesothelin chimeric antigen receptor and application thereof | 诺华股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116334143-A | Optimized lentiviral transfer vectors and uses thereof | 诺华股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-112218656-A | ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies | 诺华股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-112203725-A | BCMA chimeric antigen receptors and uses thereof | 诺华股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-106687483-B | Treatment of cancer using humanized anti-BCMA chimeric antigen receptors | 诺华股份有限公司 | 2020-12-04 | — | — | CN | disclosed |
| CN-111629749-A | Compositions and methods for selective protein degradation | 诺华股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-110832075-A | Compositions and methods for immunooncology | 诺华股份有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-110831619-A | Biomarkers and CAR T cell therapy with enhanced efficacy | 诺华股份有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-110785187-A | Antibody molecules against CD73 and uses thereof | 诺华股份有限公司 | 2020-02-11 | — | — | CN | disclosed |
| CN-110582488-A | Immune effector cell therapy with enhanced efficacy | 诺华股份有限公司 | 2019-12-17 | — | — | CN | disclosed |
| CN-110582509-A | Treatment of cancer using chimeric T cell receptor proteins with multispecific properties | 诺华股份有限公司 | 2019-12-17 | — | — | CN | disclosed |